Leukemia 2


The new prognostic markers indicate that 30-50% of the patients  have features portending a poor outcome, and therefore an early start of therapy may be justified in such poor-prognosis groups. This strategy is plausible, considering that continued proliferation and expansion of the neoplastic clone  fascilitates accumulation of ominous cytogenetic abnormalities. However, before any recommended guidelines can be proposed, clinical trials must test the use of early intervention in patients in poor prognosis groups.                                                                                                              ,

About azaleaazelia

A nice person... :)
This entry was posted in Tak Berkategori. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s